Monte Rosa Therapeutics Stock (NASDAQ:GLUE)



Previous Close

$6.78

52W Range

$3.21 - $12.40

50D Avg

$6.93

200D Avg

$5.88

Market Cap

$402.41M

Avg Vol (3M)

$1.13M

Beta

1.46

Div Yield

-

GLUE Company Profile


Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

133

IPO Date

Jun 24, 2021

Website

GLUE Performance


GLUE Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-143.31M$-112.38M$-72.88M
Net Income$-135.35M$-104.62M$-71.94M
EBITDA$-143.31M$-112.50M$-72.72M
Basic EPS-$-2.22$-2.88
Diluted EPS-$-2.22$-2.88

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
FHTXFoghorn Therapeutics Inc.
STOKStoke Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
NKTXNkarta, Inc.
NRIXNurix Therapeutics, Inc.
SANASana Biotechnology, Inc.
HOWLWerewolf Therapeutics, Inc.
LYELLyell Immunopharma, Inc.
KYMRKymera Therapeutics, Inc.
ERASErasca, Inc.
IKNAIkena Oncology, Inc.
GBIOGeneration Bio Co.
STTKShattuck Labs, Inc.